LAVA Therapeutics N.V. (LVTX)
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.
The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies.
LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use.
The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
|IPO Date||Mar 25, 2021|
Utrecht 3584 CM
|Phone||31 630 00 30 35|
|Fiscal Year||January - December|
|Stephen Allen Hurly M.B.A., M.Sc.||Chief Executive Officer and Executive Director|
|Peter Ros||Vice President of Finance|
|Dr. Hans van der Vliet M.D., Ph.D.||Chief Scientific Officer|
|Amy Garabedian J.D.||General Counsel and Corporate Secretary|
|Wouter van Hunnik||Vice President and Head of Human Resources|
|Dr. Benjamin Winograd M.D., Ph.D.||Chief Medical Officer|
|Dr. Ton Adang Ph.D.||Chief Development Officer|
|Dr. Paul W. H. I. Parren Ph.D.||Executive Vice President, Head of Research & Development and MD|
Latest SEC Filings
|Apr 22, 2022||EFFECT||Notice of Effectiveness|
|Apr 12, 2022||F-3||Registration statement by foreign private issuers|
|Mar 28, 2022||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|Mar 24, 2022||20-F||Annual and transition report of foreign private issuers [Sections 13 or 15(d)]|
|Feb 14, 2022||SC 13G/A||Statement of acquisition of beneficial ownership by individuals|
|Jan 7, 2022||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|Nov 15, 2021||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|Oct 13, 2021||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|Aug 16, 2021||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|May 28, 2021||S-8||Securities to be offered to employees in employee benefit plans|
|View All SEC Filings|